Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Income from Non-Controlling Interests: 2009-2024

Historic Income from Non-Controlling Interests for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to $27,000.

  • Lineage Cell Therapeutics' Income from Non-Controlling Interests fell 12.12% to $29,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $148,000, marking a year-over-year increase of 127.69%. This contributed to the annual value of $27,000 for FY2024, which is 285.71% up from last year.
  • As of FY2024, Lineage Cell Therapeutics' Income from Non-Controlling Interests stood at $27,000, which was up 285.71% from $7,000 recorded in FY2023.
  • In the past 5 years, Lineage Cell Therapeutics' Income from Non-Controlling Interests registered a high of $27,000 during FY2024, and its lowest value of -$251,000 during FY2021.
  • Its 3-year average for Income from Non-Controlling Interests is -$15,333, with a median of $7,000 in 2023.
  • In the last 5 years, Lineage Cell Therapeutics' Income from Non-Controlling Interests tumbled by 597.22% in 2021 and then skyrocketed by 285.71% in 2024.
  • Over the past 5 years, Lineage Cell Therapeutics' Income from Non-Controlling Interests (Yearly) stood at -$36,000 in 2020, then crashed by 597.22% to -$251,000 in 2021, then spiked by 68.13% to -$80,000 in 2022, then spiked by 108.75% to $7,000 in 2023, then surged by 285.71% to $27,000 in 2024.